Polaris Market Research today announced findings from its latest report, projecting the global DNA Manufacturing Market to grow from USD 5.59 billion in 2024 to USD 21.82 billion by 2034, at a CAGR of 14.62% from 2025 to 2034. The report profiles 13 leading companies across 4 market segments.

DNA manufacturing covers the production of plasmid and synthetic DNA molecules used across gene therapy, mRNA vaccines, diagnostics, and agricultural biotechnology. As more of these applications move from research bench to commercial and clinical scale, the market has evolved from a niche research-tools category into critical infrastructure for the broader biopharmaceutical industry.

Analyst Commentary on DNA Manufacturing Market Growth

"The DNA manufacturing market is no longer just a research-tools story, it is now core infrastructure for gene therapy, mRNA vaccines, and CRISPR-based medicine." said a Research Director at Polaris Market Research. "Buyers should watch GMP-grade capacity closely, since clinical-grade DNA supply is becoming the bottleneck for many gene-therapy programs."

Key Growth Drivers, Major Companies and Segments Covered

Growth Drivers: the rising number of gene and cell therapy programs in clinical development, growing government funding for genomics and personalized medicine, and increasing use of AI in DNA construct design and optimization are the primary forces behind the market's expansion, alongside growing demand for gene therapy. The National Library of Medicine estimates global rare-disease prevalence at 3.5% to 5.9% of the world's population, a patient base that is driving sustained demand for custom plasmids, viral vectors, and synthetic genes.

High production costs and complex regulatory requirements remain real restraints, particularly for smaller biotech startups and academic labs with limited budgets, a dynamic that is pushing much of that demand toward contract research organizations with the scale and compliance infrastructure to serve them cost-effectively.

Major Companies Covered: 

• Catalent
• Charles River Laboratories
• Elegen
• Eurofins Genomics
• GenScript
• Kaneka Corp
• ProBio
• Thermo Fisher Scientific
• Touchlight
• VGXI, Inc.
• Wuxi AppTec

Browse More Information:

https://www.polarismarketresearch.com/industry-analysis/dna-manufacturing-market 

Segments Covered: By Type (Plasmid DNA, Synthetic DNA), By Grade (GMP Grade, R&D Grade), By Application (Cell & Gene Therapy, Vaccines, Oligonucleotide-Based Drugs), and By End Use (Pharmaceutical and Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations).

The grade split is especially telling: GMP-grade DNA, manufactured under strict quality controls to meet FDA and EMA standards, commands the larger share precisely because so much current demand is tied to active clinical trials and approved therapies rather than early-stage research.

Recent Developments in the DNA Manufacturing Market

• May 2025: VGXI, Inc. successfully passed an FDA inspection at its Conroe, Texas site, enabling a client to file a Biologics License Application for plasmid DNA in gene therapies and mRNA vaccines.
• January 2025: Elegen launched ENFINIA Plasmid DNA, a faster, cost-effective solution for clonal synthesis of long and complex genes.

Regional Snapshot: North America Leads, Asia Pacific Fastest-Growing

North America led with 47.38% share in 2024, supported by its mature biotechnology ecosystem, early adoption of synthetic biology tools, and substantial funding for gene-based therapeutics, while Asia Pacific is projected to register the fastest growth through 2034 on the back of expanding biopharmaceutical R&D investment and government-backed genomics initiatives in China, Japan, and South Korea.

Europe is expected to hold a substantial share through 2034 on the strength of the EU's Horizon Europe funding program and pharmaceutical hubs in Germany, the UK, and Switzerland, while India's biopharmaceutical and vaccine industries are emerging as a notable growth story supported by "Make in India" incentives.

Why It Matters for DNA manufacturing market forecast

For stakeholders researching the DNA manufacturing market forecast, the underlying report benchmarks DNA Manufacturing Market share, company positioning, and segment-level forecasts to support sourcing, partnership, and investment decisions through 2034. For biopharma sourcing teams, the data highlights that GMP-grade capacity, not raw production volume, is often the real constraint when planning clinical-stage DNA supply.

Conclusion

The DNA Manufacturing Market is moving forward as biotechnology, pharmaceutical research, and personalized medicine continue to develop. Growing interest in synthetic DNA for research, drug development, diagnostics, and other applications is creating new opportunities for manufacturers. As DNA production becomes faster, more accurate, and more accessible, the market is expected to play an increasingly important role in supporting innovation across the life sciences industry.

More Trending Latest Reports By Polaris Market Research:

Semiconductor Memory Market

Catalog Management System Market

Regenerative Meat Market

Tickling the Tastebuds with Guanylic Acid Market

Bottled Water Processing Market

Bottled Water Processing Market

Automotive Oil Recycling Market

Legionella Testing Market

Process Automation and Instrumentation Market